[Skip to Content]
[Skip to Content Landing]
Views 2,702
Citations 0
Research Letter
May 19, 2020

Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans

Author Affiliations
  • 1Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts
JAMA. 2020;323(19):1972-1973. doi:10.1001/jama.2020.2229

The greater use of biosimilars may have the potential to help reduce drug costs. However, biosimilars have yet to gain traction in the US.1 In 2010, Congress created an abbreviated licensure pathway for biosimilars, but it is unclear whether and how health plans prioritize coverage of these products.2,3 We examined how commercial health plans cover biosimilars relative to reference products.